VAERS data released by the CDC showed a total of 387,087 reports of adverse events from all age groups following COVID vaccines, including 6,113 deaths and 31,240 serious injuries between Dec. 14, 2020 and June 18, 2021.

This week’s number of reported deaths among all age groups following COVID vaccines surpassed 6,000 according to data released today by the Centers for Disease Control and Prevention (CDC). The data comes directly from reports submitted to the Vaccine Adverse Event Reporting System (VAERS).

VAERS is the primary government-funded system for reporting adverse vaccine reactions in the U.S. Reports submitted to VAERS require further investigation before a causal relationship can be confirmed.

Every Friday, VAERS makes public all vaccine injury reports received as of a specified date, usually about a week prior to the release date.

Data released today show that between Dec. 14, 2020 and June 18, 2021, a total of 387,087 total adverse events were reported to VAERS, including 6,113 deaths — an increase of 120 deaths over the previous week. There were 31,240 serious injury reports, up 1,369 compared with last week.

In the U.S. 316.1 million COVID vaccine doses had been administered as of June 18. This includes: 131 million doses of Moderna’s vaccine, 173 million doses of Pfizer and 12 million doses of the Johnson & Johnson (J&J) COVID vaccine.

Of the 6,113 deaths reported as of June 18, 23% occurred within 48 hours of vaccination, 16% occurred within 24 hours and 38% occurred in people who became ill within 48 hours of being vaccinated.

This week’s data for 12- to 17-year-olds showed 7,294 total adverse events, including 423 rated as serious and nine reported deaths among 12- to 17-year-olds. Four deaths (or 44%) were cardiac-related and three were sudden, unexplained deaths.

The most recent reported death includes a 13-year-old boy (VAERS I.D. 1406840) who died two days after receiving a Pfizer vaccine. Other deaths include three 15-year-olds (VAERS I.D. 1187918, 1382906 and 1242573) and two 16-year-olds (VAERS I.D. 1225942 and 1386841) and one 17-year-old (VAERS I.D. 1199455).

The report of a 15-year-old male (VAERS I.D. 1383620) who reportedly died after receiving a Pfizer vaccine was removed from the database on June 18. It was a duplicate of VAERS I.D. 1382096. Two of the nine deaths were suicides.

The 1,164 reports of anaphylaxis among 12- to17-year-olds with 99% of cases attributed to Pfizer’s vaccine, 1.2% to Moderna and 0.2% (or two cases) to J&J.

The 171 reports of myocarditis and pericarditis (heart inflammation) with 169 attributed to Pfizer’s COVID vaccine.

28 reports of blood clotting disorders, all attributed to Pfizer.

This week’s total VAERS data, from Dec. 14, 2020 to June 18, 2021, for all age groups show: 21% of deaths were related to cardiac disorders, 51% of those who died were male, 45% were female and the remaining death reports did not include gender of the deceased. The average age of death was 74.2.

As of June 18, some 2,222 pregnant women reported adverse events related to COVID vaccines, including 737 reports of miscarriage or premature birth.

Of the 3,764 cases of Bell’s Palsy reported, 54% were attributed to Pfizer vaccinations, 43% to Moderna vaccine and 8% to J&J.

The 344 reports of Guillain-Barré Syndrome, with 45% of cases attributed to Pfizer, 41% to Moderna and 20% to J&J.

The 107,909 reports of anaphylaxis with 43% of cases attributed to Pfizer’s vaccine, 49% to Moderna and 8% to J&J.

The 6,787 reports of blood clotting disorders. Of those, 2,892 reports were attributed to Pfizer, 2,394 reports to Moderna and 1,459 reports to J&J.

Some 1,342 cases of myocarditis and pericarditis with 835 cases attributed to Pfizer, 458 cases to Moderna and 45 cases to J&J’s COVID vaccine.

As The Defender reported June 23, the CDC’s Advisory Committee on Immunization Practices (ACIP) said there is a “likely association” of “mild” heart inflammation in adolescents and young adults after vaccination.

Members of a CDC advisory committee acknowledged 1,200 cases of heart inflammation in 16- to 24-year-olds, mostly occurring in males, and said mRNA COVID vaccines should carry a warning statement — but physicians and other public commenters accused the CDC of exaggerating the risk to young people of COVID, and minimizing the risk of the vaccines.

Dr. Tom Shimabukuro, deputy director of the CDC’s Immunization Safety Office, said in a presentation that data from one of the agency’s safety monitoring systems — Vaccine Safety Datalink (VSD) — suggests a rate of 12.6 cases per million in 12- to 39-year-olds during the three weeks after the second shot.

The Defender has been unable to report on VSD data related to COVID vaccine adverse events, including heart inflammation, as the VSD does not make data collected through the system readily available to the public.

The VSD is a collaborative project between the CDC and “several large health plans,” according to its website. Though the public can’t access the VSD data, there is a process whereby researchers can apply to access data.

According to the VSD website: “There are several ways interested researchers can access VSD data. In 2002, the VSD established a data sharing program at the National Center for Health Statistics (NCHS) Research Data Center (RDC) to allow external Guest Analysts to (1) conduct new vaccine safety studies using VSD data files available at CDC or (2) to reanalyze study-specific datasets from published VSD studies.”

The VSD data sharing program is a three-step process: Submission of proposals to CDC’s RDC at NCHS; Submission of proposals to VSD site Institutional Review Boards; and Use of CDC’s RDC at NCHS.

FDA to add warning about rare heart inflammation to Pfizer and Moderna vaccines

On June 24, The Guardian reported the U.S. Food and Drug Administration will add a warning to COVID vaccines produced by Pfizer /BioNTech and Moderna about rare cases of heart inflammation in adolescents and young adults, the agency announced Wednesday.

Health regulators in several countries have been investigating whether the Pfizer and Moderna vaccines using mRNA technology present a risk and, if so, how serious. The CDC advisory group found the inflammation in adolescents and young adults is likely linked to the vaccines, but the benefits of the shots outweigh the risk.

The 18-year-old has a heart attack after a second dose of Pfizer vaccine

As The Defender reported June 22, 18-year-old Isaiah Harris was hospitalized after suffering a heart attack within 48 hours of his second dose of the Pfizer vaccine and is on total bed rest for six months. Isaiah Harris and his father, Justin Harris, described the traumatic ordeal in an exclusive interview.

“We took him to the hospital but they didn’t take him seriously,” Harris said. “We waited in the waiting room for over two hours and then they left him in a hallway for six hours. Things went from bad to worse while waiting in the hospital. That’s when he had his heart attack and one of his lungs filled up with fluid.”

At one point, 80% of Isaiah’s heart was inflamed and only 40% was functioning. Isaiah’s troponin levels were so high doctors said he had suffered a heart attack. According to Harris, doctors kept denying it was the vaccine until a nurse brought in a study showing the vaccine could cause myocarditis.

Harris believes his son would have been better off to have COVID versus the possible life-long issues he is now facing with his heart and the possibility of another heart attack if he overextends himself in the next three to six months. Isaiah said he would rather have COVID than a heart attack.\Datalink (VSD) — suggests a rate of 12.6 cases per million in 12- to 39-year-olds during the three weeks after the second shot.

The Defender has been unable to report on VSD data related to COVID vaccine adverse events, including heart inflammation, as the VSD does not make data collected through the system readily available to the public.

The VSD is a collaborative project between the CDC and “several large health plans,” according to its website. Though the public can’t access the VSD data, there is a process whereby researchers can apply to access data.

According to the VSD website: “There are several ways interested researchers can access VSD data. In 2002, the VSD established a data sharing program at the National Center for Health Statistics (NCHS) Research Data Center (RDC) to allow external Guest Analysts to (1) conduct new vaccine safety studies using VSD data files available at CDC or (2) to reanalyze study-specific datasets from published VSD studies.”

The VSD data sharing program is a three-step process: Submission of proposals to CDC’s RDC at NCHS; Submission of proposals to VSD site Institutional Review Boards; and Use of CDC’s RDC at NCHS.

By Megan Redshaw